Pushparaj P et al., 2026-07-31: Prospective series of ten surgical patients with type I congenital methemoglobinemia found incidentally, in whom methylene blue was held in reserve for symptomatic cases.
Management was largely supportive, with methylene blue reserved for symptomatic individuals.
Pushparaj P et al., 2026-07-31: Prospective series of ten surgical patients with type I congenital methemoglobinemia found incidentally, in whom methylene blue was held in reserve for symptomatic cases. C4. Study type: prospective case series, N=10, one year, Jubilee Mission Medical College and Research Institute, Thrissur, Kerala, India. MetHb 14.4-29.1%; all type I by erythrocyte NADH-cytochrome b5 reductase assay; most asymptomatic or mildly symptomatic with a saturation gap. Methylene blue dose not stated in the abstract; no chronic-use data. Funder/conflicts not stated in the PubMed record. Supports the practice that congenital type I cases are often managed without methylene blue. Study type: uncontrolled series.
